{
  "ticker": "NTI",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966571",
  "id": "02966571",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250707",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljmzpygsqkww.pdf",
  "summary": "- **Clinical Trial Results Publication**:  \n  - Phase I/II Rett syndrome trial results for NTI164 (0.08% THC medicinal cannabis extract) published in *Journal of Paediatrics and Child Health*.  \n  - **Key findings**:  \n    - Well-tolerated with clinical improvements in neurological, behavioural, and functional measures.  \n    - Potential broader therapeutic benefits for Rett syndrome.  \n\n- **Regulatory/Therapeutic Implications**:  \n  - Peer-reviewed validation supports NTI164\u2019s mechanism (targeting neuroinflammation/glial dysregulation) and potential for future regulatory advancement.  \n\n*No material trading or capital markets actions (e.g., raising, timetable) identified.*",
  "usage": {
    "prompt_tokens": 1165,
    "completion_tokens": 144,
    "total_tokens": 1309,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T00:04:34.389847"
}